The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Evaluating the addition of venetoclax to a chemotherapy backbone in pediatric AML patients
Gwen Nichols, MD, Leukemia & Lymphoma Society, New York, NY, shares some insights into unmet needs in pediatric acute myeloid leukemia (AML), and further discusses a novel clinical trial which will evaluate the randomized addition of venetoclax to a chemotherapy backbone in children with relapsed AML (NCT05183035). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
